Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis

NCT04878003 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Myelofibrosis (PMF)
Post-Polycythemia Vera Myelofibrosis (Post-PV-MF)
Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)

Interventions

DRUG: KRT-232
DRUG: TL-895

Sponsor

Kartos Therapeutics, Inc.